[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (209)

Search Parameters:
Keywords = glycaemia

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
21 pages, 480 KiB  
Article
Associations Between Carbohydrate Intake Behaviours and Glycaemia in Gestational Diabetes: A Prospective Observational Study
by Roslyn Smith, Renee Borg, Vincent Wong, Hamish Russell and Ka Hi Mak
Nutrients 2025, 17(3), 400; https://doi.org/10.3390/nu17030400 - 22 Jan 2025
Viewed by 529
Abstract
Carbohydrate intake (CI) has the largest impact on the short-term glycaemia of all nutrients, yet optimal CI management in gestational diabetes remains unclear. Objective: To examine CI behaviours in individuals with recently diagnosed gestational diabetes and their association with self-monitored blood glucose. Methods: [...] Read more.
Carbohydrate intake (CI) has the largest impact on the short-term glycaemia of all nutrients, yet optimal CI management in gestational diabetes remains unclear. Objective: To examine CI behaviours in individuals with recently diagnosed gestational diabetes and their association with self-monitored blood glucose. Methods: Data from 97 individuals were collected using food and blood glucose diaries. CI (including amounts, types, and timing) was manually assessed using 15 g servings over 5–8 days, while a 3-day computerised analysis examined a broader intake of macro- and micronutrients. Results: Elevated fasting glycaemia (EFG) was associated with lower total CI (Mdn 10.8 vs. 12.5 servings/day, p = 0.006), missed meals (Mdn 1.4 vs. 0.0/week, p = 0.007), missed snacks (Mdn 10.5 vs. 7.5/week, p = 0.038), low-carbohydrate meals (<30 g; Mdn 4.3 vs. 2.0/week, p = 0.004), and a higher proportion of energy intake from fat (Mdn 35% vs. 33%, p = 0.047), as compared with in-target fasting glycaemia. In contrast, elevated postprandial glycaemia (EPG) was not significantly associated with total CI, low-carbohydrate meals (<30 g), low-carbohydrate snacks (<15 g), or high-carbohydrate loads (>50 g). EPG was instead associated with high-glycaemic index meals (Mdn 1.6 vs. 0.9 lunch meals/week, p = 0.026; Mdn 0.9 vs. 0.0 dinner meals/week, p = 0.023); and a lower intake of energy (Mdn 7650 kJ vs. 9070 kJ/day, p = 0.031), protein (Mdn 91 g vs. 109 g/day, p = 0.015), fat (Mdn 61 g vs. 84 g/day, p = 0.003), and multiple micronutrients (p <0.05), as compared with in-target postprandial glycaemia. Conclusions: CI profiles differed for individuals with EFG, as compared with EPG, emphasising the need for dietary guidelines tailored for gestational diabetes subtypes. Further interventional studies are needed to explore these findings, particularly the associations between EFG and low CI behaviours. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Carbohydrate intake considerations in gestational diabetes based on current evidence. <sup>a</sup> [<a href="#B15-nutrients-17-00400" class="html-bibr">15</a>], <sup>b</sup> [<a href="#B5-nutrients-17-00400" class="html-bibr">5</a>], <sup>c</sup> [<a href="#B8-nutrients-17-00400" class="html-bibr">8</a>], <sup>d</sup> [<a href="#B7-nutrients-17-00400" class="html-bibr">7</a>], <sup>e</sup> [<a href="#B8-nutrients-17-00400" class="html-bibr">8</a>,<a href="#B9-nutrients-17-00400" class="html-bibr">9</a>,<a href="#B20-nutrients-17-00400" class="html-bibr">20</a>], <sup>f</sup> [<a href="#B7-nutrients-17-00400" class="html-bibr">7</a>,<a href="#B9-nutrients-17-00400" class="html-bibr">9</a>,<a href="#B10-nutrients-17-00400" class="html-bibr">10</a>], <sup>g</sup> [<a href="#B11-nutrients-17-00400" class="html-bibr">11</a>], <sup>h</sup> [<a href="#B12-nutrients-17-00400" class="html-bibr">12</a>,<a href="#B13-nutrients-17-00400" class="html-bibr">13</a>], <sup>i</sup> [<a href="#B16-nutrients-17-00400" class="html-bibr">16</a>,<a href="#B17-nutrients-17-00400" class="html-bibr">17</a>].</p>
Full article ">
20 pages, 25587 KiB  
Article
Combining In Vitro, In Vivo, and In Silico Approaches to Explore the Effect of Ceratonia siliqua and Ocimum basilicum Rich Phenolic Formula on Lipid Metabolism and Plasma Lipoprotein Oxidation in Mice Fed a High-Fat Diet: A Follow-Up Study
by Mohammadine Moumou, Amani Tayebi, Abderrahmane Hadini, Omar M. Noman, Abdulsalam Alhalmi, Hamza Ahmoda, Souliman Amrani and Hicham Harnafi
Metabolites 2025, 15(1), 36; https://doi.org/10.3390/metabo15010036 - 10 Jan 2025
Viewed by 494
Abstract
Background/Objectives: Hyperlipidemia is a serious risk factor for cardiovascular diseases and liver steatosis. In this work, we explored the effect of an herbal formula (CBF) containing immature Ceratonia siliqua pods and Ocimum basilicum extracts on lipid metabolism disorders and lipoprotein-rich plasma (LRP) oxidation [...] Read more.
Background/Objectives: Hyperlipidemia is a serious risk factor for cardiovascular diseases and liver steatosis. In this work, we explored the effect of an herbal formula (CBF) containing immature Ceratonia siliqua pods and Ocimum basilicum extracts on lipid metabolism disorders and lipoprotein-rich plasma (LRP) oxidation in mice. Methods: The phenolic composition was determined using HPLC-DAD analysis. The antioxidant activity was studied using various in vitro methods. Acute toxicity was evaluated in mice. Importantly, the effect of the CBF on lipid metabolism disorders was investigated in a high-fat diet (HFD) hyperlipidemia mouse model. An in silico study was carried out to predict underlying mechanisms. Results: The HPLC analysis revealed gallic acid, cinnamic acid, and naringenin as major phenolics of the carob pod aqueous extract. Concerning the basil hydro-ethanolic extract, rosmarinic, chicoric, caftaric, and caffeic acids were the main phenolics. Accordingly, the CBF prevented LRP oxidation in a concentration-dependent manner. This formula is not toxic in mice (LD50 > 2000 mg/kg body weight). Moreover, animals administered the CBF at 200 mg/kg/day presented a significant decline in their body weight gain, adipose tissue weight, plasma total cholesterol, low-density lipoprotein cholesterol (LDL-C) level, and glycaemia after 10 weeks’ treatment. Accordingly, the CBF decreased the plasma atherogenic index and the LDL-C to HDL-C ratio and reduced the level of fats accumulated in the liver. The molecular docking study revealed that chicoric, rosmarinic, and caftaric acids, and naringenin bound particularly strongly to many proteins involved in the regulation of lipid and cholesterol metabolism. This includes the HMG-CoA reductase, PPARα/γ, PCSK9, Cyp7a1, and ATP-citrate lyase. Conclusions: The CBF could be a good source of natural supplements, functional foods, and pharmaceuticals effective in managing hyperlipidemia and oxidative stress and preventing their related cardiovascular disorders. Full article
(This article belongs to the Section Food Metabolomics)
Show Figures

Figure 1

Figure 1
<p>HPLC phenolic profiles of <span class="html-italic">C. siliqua</span> (<b>A</b>) and <span class="html-italic">O. basilicum</span> (<b>B</b>) extracts.</p>
Full article ">Figure 2
<p>Chemical structures of the main phenolics from the immature carob pod aqueous extract and sweet basil hydro-ethanolic extract. 1: Quercetin (CID: 5280343); 2: rosmarinic acid (CID: 5281792); 3: gallic acid (CID: 370); 4: caftaric acid (CID: 64409397); 5: cinnamic acid (CID: 444539); 6: caffeic acid (CID 689043); 7: naringenin (CID: 439246); 8: chicoric acid (CID:528176) (Drawn using ChemDraw Pro 12 software).</p>
Full article ">Figure 3
<p>Concentration-dependent DPPH radical scavenging activity of the CBF and BHA (<b>A</b>) and the obtained IC<sub>50</sub> values (<b>B</b>). Ferric reducing power activity of the CBF and AA (<b>C</b>) and the obtained EC<sub>50</sub> values (<b>D</b>). Effect of CBF and AA on mice LRP oxidation (<b>E</b>) and the corresponding IC<sub>50</sub> values (<b>F</b>). Results are represented as mean ± SEM (<span class="html-italic">n</span> = 3). CBF: carob/basil formula; AA: ascorbic acid; BHA: butylated hydroxyanisole. * <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 4
<p>Effect of the CBF and fenofibrate on plasma TC (<b>A</b>), TG (<b>B</b>), LDL-C (<b>C</b>), and HDL-C (<b>D</b>) levels, the atherogenic index (<b>E</b>), LDL-C/HDL-C ratio (<b>F</b>), glycaemia (<b>G</b>), hepatic TG (<b>H</b>), and TC (<b>I</b>) levels in mice (<span class="html-italic">n</span> = 6) fed HFD for 10 consecutive weeks. NLC: normal control; HLC: hyperlipidemic control; CBFG; CBF-treated mice; FFG; fenofibrate-treated mice. <sup>#</sup> <span class="html-italic">p</span> &lt; 0.001 vs. NLC; * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01 vs. HLC.</p>
Full article ">Figure 5
<p>Heat map showed the binding energy (kcal/moL) between the CBF phenolics and main targets involved in the regulation of lipid metabolism. ACLY: ATP-citrate lyase; HMG−CoAR: β−hydroxy β−methylglutaryl−CoA reductase; PPAR: peroxisome proliferator activated receptors; LXRα: liver X receptor alpha; LPL: lipoprotein lipase; PCSK9: proprotein convertase subtilisin/kexin type 9; RXR: retinoid X receptors; Cyp7a1: cytochrome P450, family 7, subfamily a, polypeptide 1; C/EBPα: CCAAT/enhancer binding protein alpha; FXR: farnesoid X receptors; FAS: fatty acid synthase; NPC1L1: Niemann–Pick C1−Like 1.</p>
Full article ">Figure 6
<p>Interactions between CBF phenolics/fenofibrate and the main proteins involved in the regulation of lipid metabolism (3D and 2D structures). (<b>A</b>): chicoric acid/HMGCoA reductase; (<b>B</b>): rosmarinic/PPARα; (<b>C</b>): gallic acid/RXRα; (<b>D</b>): fenofibrate/PPARα.</p>
Full article ">Figure 7
<p>Interactions between CBF phenolics and main proteins involved in the regulation of lipid metabolism (3D and 2D structures). (<b>A</b>): naringenin/LXRα; (<b>B</b>): chicoric acid/FAS: (<b>C</b>): rosmarinic acid/ACLY; (<b>D</b>): naringenin/PCSK9.</p>
Full article ">
13 pages, 949 KiB  
Article
Pregnancy Complications and Outcomes in Obese Women with Gestational Diabetes
by Gitana Ramonienė, Laura Malakauskienė, Eglė Savukynė, Laima Maleckienė and Greta Gruzdaitė
Medicina 2025, 61(1), 51; https://doi.org/10.3390/medicina61010051 - 1 Jan 2025
Viewed by 493
Abstract
Background and Objectives: To assess pregnancy and delivery complications in obese women with gestational diabetes mellitus (GDM) and neonatal weight and condition after birth. Materials and Methods: A retrospective tertiary referral centre study included all cases of GDM in the Department [...] Read more.
Background and Objectives: To assess pregnancy and delivery complications in obese women with gestational diabetes mellitus (GDM) and neonatal weight and condition after birth. Materials and Methods: A retrospective tertiary referral centre study included all cases of GDM in the Department of Obstetrics and Gynaecology of the Lithuanian University of Health Sciences (LUHS) Birth Registry from 1 January 2019 to 31 December 2019. We included 583 women with GDM and singleton pregnancies. Women were divided into two groups according to their pre-pregnancy weight: 202 were obese (BMI ≥ 30 kg/m2), and 381 were weight (BMI 18.5–24.9 kg/m2). Survey data were analysed using IBM SPSS Statistics 26.0 and MS Excel 2016 software. A value of p < 0.05 was considered significant. Results: Fasting glycaemia was significantly higher in obese women with GDM than in normal-weight women with GDM (p < 0.001). In addition, fasting glycaemia was higher in obese women with GDM requiring insulin correction than in normal-weight women (p = 0.006). OGTT 0-min glycaemia was higher in obese than in non-obese women with gestational diabetes (p < 0.001). Women with pre-pregnancy obesity had a higher incidence of primary hypertension (p < 0.001), hypertensive disorders in pregnancy (p < 0.001), gestational cholestasis (p = 0.002), polyhydramnios (p < 0.001), induced labour (p < 0.001), and caesarean section (p = 0.015), with emergency caesarean sections being more frequent than planned caesarean sections (p = 0.011) compared to normal-weight women with GDM. Labour dystocia (p = 0.003) and foetal distress (p = 0,019) were more common during labour in obese women. Neonates of these women more often had macrosomia (p < 0.001) and lower Apgar scores at 1 min (p = 0.024) and at 5 min (p = 0.024) compared to neonates of normal-weight women. Conclusions: Obese women with GDM experience more pregnancy complications than normal-weight women with GDM. Full article
(This article belongs to the Section Obstetrics and Gynecology)
Show Figures

Figure 1

Figure 1
<p>Distribution of normal-body-weight and obese pregnant women by amount of amniotic fluid (%) (N = 583). * <span class="html-italic">p</span> &lt; 0.001 compared to women with normal body weight (z test with Bonferroni correction).</p>
Full article ">Figure 2
<p>Distribution of normal-body-weight and obese pregnant women according to the causes for a C-section (N = 112). <span class="html-italic">p</span> = 0.032; *—<span class="html-italic">p</span> &lt; 0.05, compared to women with normal body weight (z test with Bonferroni correction).</p>
Full article ">
8 pages, 209 KiB  
Article
Impact of Intensive Insulin Stabilisation Service in Pregnancy with Type 1 Diabetes
by Stephanie Teasdale, Natasha Cannon, Alison Griffin, Janelle Nisbet and H. David McIntyre
Reprod. Med. 2024, 5(4), 302-309; https://doi.org/10.3390/reprodmed5040026 - 5 Dec 2024
Viewed by 710
Abstract
Background/Objectives: Adverse pregnancy outcomes correlate with blood glucose levels in women with type 1 diabetes (T1DM). There is a gap between the glycaemic targets and the blood glucose control achieved in pregnancy. This study aimed to investigate the impact of an intensive weekly [...] Read more.
Background/Objectives: Adverse pregnancy outcomes correlate with blood glucose levels in women with type 1 diabetes (T1DM). There is a gap between the glycaemic targets and the blood glucose control achieved in pregnancy. This study aimed to investigate the impact of an intensive weekly service on glycaemic control compared with our previous care model in pregnancies affected by T1DM. Materials and Methods: This is a retrospective cross-sectional pre/post study comparing measures of glycaemic control in women with T1DM in each trimester of pregnancy in the 12 months before and the 8 months after the commencement of an intensive weekly insulin stabilisation service (ISS). Results: This study utilised data from Dexcom continuous glucose monitoring (CGM) reports to analyse pregnancy-specific glycaemic data (incorporating time in the range of 3.5–7.8 mmol/L). In total, 16 women provided data for 35 trimesters pre-ISS and 17 women provided data for 38 trimesters post-ISS. There was an improvement in pregnancy-specific time in range in trimester 3 following the commencement of the intensive weekly insulin stabilisation service (pre-ISS mean: 49.6%, post-ISS mean: 61.4%, p = 0.042). Similar results were seen when women using hybrid closed-loop technology were excluded, although statistical significance was not reached. It was not possible to assess the effect of the intervention during the first trimester. There were no statistically significant changes in glycaemia in trimester 2. Conclusions: In a small group of pregnant women with T1DM, a clinically significant improvement in pregnancy-specific time in range occurred in trimester 3, but not in trimester 1 or 2, following the introduction of intensive weekly clinical support. Full article
19 pages, 498 KiB  
Article
Predictive Models of Atherogenic Risk in Citizens of Trujillo (Peru) Based on Associated Factors
by Jackeline del Pilar Bustamante Gallo, Cinthya Stephany Neglia Cermeño, Jorge Luis Díaz-Ortega and Irma Luz Yupari-Azabache
Nutrients 2024, 16(23), 4138; https://doi.org/10.3390/nu16234138 - 29 Nov 2024
Viewed by 683
Abstract
Background/objectives: Atherogenic risk is related to lipid metabolism imbalance and the likelihood of cardiovascular disease (CVD). The purpose of this study was to determine predictive models based on physiological parameters, family history, and lifestyle for atherogenic risk, assessed by indicators such as total [...] Read more.
Background/objectives: Atherogenic risk is related to lipid metabolism imbalance and the likelihood of cardiovascular disease (CVD). The purpose of this study was to determine predictive models based on physiological parameters, family history, and lifestyle for atherogenic risk, assessed by indicators such as total cholesterol (TC)/HDL, triglycerides/HDL, LDL/HDL, and non-HDL cholesterol in citizens of the city of Trujillo (Peru). Methods: A total of 267 people, recruited from September to December 2023, participated in the study. Their lipid profile, glycaemia, abdominal perimeter, and blood pressure were determined, and questionnaires were applied with questions on diet, physical activity, alcohol consumption, smoking, hours of sleep, and family history. Binary logistic regression was considered to determine prediction models for each atherogenic risk indicator. Results: High values were found for all atherogenic indicators; dietary habits were poor in 86.1%; physical activity was low in 35.2%; hours of sleep were less than 7 h in 64.4%; and alcohol and tobacco consumption were low in 8.2% and 9%, respectively. The family history of CVD corresponded to the mother, father, grandmother, and grandfather in 53.2%, 44.9%, 30.3% and 25.1%, respectively. In addition to the inclusion of BMI in the predictive models of atherogenic risk, for the case of total cholesterol/HDL, the variable grandparental history and female sex were included; for TG/HDL, low physical activity, male sex, and alcohol consumption were associated; and for LDL/HDL and non-HDL cholesterol, female sex and age were associated. Conclusion: The best prediction model for atherogenic risk is the corresponding model for TG/HDL, without ignoring the grandfather’s history of CVD and age. Full article
(This article belongs to the Section Lipids)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Flow diagram of subject inclusion and exclusion.</p>
Full article ">
10 pages, 1088 KiB  
Article
Keto Analogues in Patients with Chronic Kidney Disease with or Without Kidney Transplantation
by Patrícia Kleinová, Tímea Blichová, Karol Graňák, Andrej Kollár, Matej Vnučák and Ivana Dedinská
Nutrients 2024, 16(23), 4001; https://doi.org/10.3390/nu16234001 - 22 Nov 2024
Viewed by 764
Abstract
Background: Keto analogues in combination with a (very) low-protein diet significantly reduces the progression to end-stage kidney disease. The question of their benefit and safety for kidney transplant recipients remains. This study aimed to show the renoprotective effect and safety of the use [...] Read more.
Background: Keto analogues in combination with a (very) low-protein diet significantly reduces the progression to end-stage kidney disease. The question of their benefit and safety for kidney transplant recipients remains. This study aimed to show the renoprotective effect and safety of the use of this method in patients with chronic kidney disease and a kidney transplantation. Materials: This was a retrospective monocentric study conducted by the transplant nephrology department in Martin, in which patients with chronic kidney disease, with or without kidney transplant therapy, who received a low-protein diet and supplementation with keto analogues were included (n = 59). The changes in their glomerular filtration rate, proteinemia, calcaemia, weight, and glycaemia and the side effects associated with a low-protein diet and keto analogue use were studied in the patients with chronic kidney disease with or without kidney transplantation. Results: The kidney transplant recipients had a significantly more advanced stage of chronic kidney disease (p = 0.0001) than the non-transplanted patients at the time of the prescription of the keto analogues (p = 0.0001). Furthermore, the kidney transplant recipients had a significantly longer follow-up period (p = 0.0001), with a difference of 27 months within subgroups. During the observed period, we recorded a decrease in glomerular filtration, but without statistical significance. In our group, we did not confirm a significant occurrence of adverse effects associated with a low-protein diet and keto analogues. Conclusion: Keto analogues reduce the progression of chronic kidney disease and stabilise glomerular filtration in patients with chronic kidney disease. Based on our analysis, treatment with keto analogues is effective and safe for kidney transplant recipients after kidney transplantation. Full article
(This article belongs to the Special Issue Nutrition and Metabolism in Chronic Kidney Diseases)
Show Figures

Figure 1

Figure 1
<p>The distribution of the cohort patients according to CKD aetiology. ADPKD—autosomal dominant polycystic kidney disease, DKD—diabetic kidney disease, TIN—tubulointersticial glomerulonephritis.</p>
Full article ">Figure 2
<p>Development of eGFR during followed period in the cohort. eGFR—estimated glomerular filtration.</p>
Full article ">Figure 3
<p>Development of eGFR in the cohort. eGFR—estimated glomerular filtration rate.</p>
Full article ">Figure 4
<p>The change of eGFR during follow-up—transplanted and non-transplanted patients. eGFR—estimated glomerular filtration rate.</p>
Full article ">
13 pages, 605 KiB  
Article
The Effect of the Oral Contraceptive Pill on Acute Glycaemic Response to an Oral Glucose Bolus in Healthy Young Women: A Randomised Crossover Study
by Julia M. E. Cree, Niamh M. Brennan, Sally D. Poppitt and Jennifer L. Miles-Chan
Nutrients 2024, 16(20), 3490; https://doi.org/10.3390/nu16203490 - 15 Oct 2024
Viewed by 1262
Abstract
Background/Objective: The oral contraceptive pill (OCP) is widely used by women worldwide, yet the influence of the OCP on carbohydrate metabolism remains under-investigated, with existing studies being few and largely cross-sectional. The study objective was to assess, for the first time, the effect [...] Read more.
Background/Objective: The oral contraceptive pill (OCP) is widely used by women worldwide, yet the influence of the OCP on carbohydrate metabolism remains under-investigated, with existing studies being few and largely cross-sectional. The study objective was to assess, for the first time, the effect of the combined OCP on postprandial glycaemic response to an oral glucose bolus, using a randomised crossover design. Methods: The effect of a combined monophasic OCP phase on glucose homeostasis and metabolic profile was investigated in 21 healthy young women, who were regular users of either androgenic or anti-androgenic OCP formulations. Plasma glycaemic markers (glucose, insulin and C-peptide) were assessed prior to a 60 g glucose drink (fasting) and for a further 4 h postprandially; once during the “active” (hormone-containing) pill phase and once during the “inactive” (hormone-free) pill phase of the OCP usage cycle. Results: Despite no change in fasting values, in androgenic pill users, postprandial glucose and insulin responses to an oral glucose bolus were ~100% and ~50% greater, respectively, during the active versus inactive phase. In contrast, in anti-androgenic pill users there was no significant change in response between the two OCP usage cycle phases. Conclusions: These findings highlight an acute, but potentially detrimental, influence of the combined OCP on glucose homeostasis, particularly in users of formulations containing androgenic progestogens. Given the high global prevalence of OCP use and increasingly common prolonged active pill regimens, which may continue for months, years or even decades, potential cumulative effects of such changes on metabolic risk demand further investigation. Full article
(This article belongs to the Section Nutrition in Women)
Show Figures

Figure 1

Figure 1
<p>Change in plasma glucose (<b>A</b>), insulin (<b>B</b>) and C-peptide (<b>C</b>) from fasting baseline over 240 min following consumption of a 60g glucose bolus. Women using oral contraceptive pills (OCPs) containing androgenic progestogens (n = 13) during the active (blue closed circles) and inactive phases (blue open circles). Women using OCPs with anti-androgenic progestogens (n = 8) during the active (red closed squares) and inactive phases (red open squares). Mean ± SEM.</p>
Full article ">Figure 2
<p>Net incremental area-under-curve (iAUC) from baseline to 240 min for plasma glucose (<b>A</b>), insulin (<b>B</b>) and C-peptide (<b>C</b>). Women using oral contraceptive pills (OCPs) containing androgenic progestogens (n = 13) during the active (blue closed circles) and inactive phases (blue open circles). Women using OCPs with anti-androgenic progestogens (n = 8) during the active (red closed squares) and inactive phases (red open squares). Significant interaction between pill type and phase observed for glucose (* <span class="html-italic">p</span> = 0.034) and C-peptide (** <span class="html-italic">p</span> = 0.005). Significant effect of pill phase observed for insulin (# <span class="html-italic">p</span> &lt; 0.001). Mean ± SEM.</p>
Full article ">
21 pages, 2895 KiB  
Article
Chemical Profiling, Enzyme Inhibitory Activity and Antioxidant Capacity of South African Herbal Teas: Buddleja saligna, Lippia javanica, L. scaberrima and Phyla dulcis
by Nélida Nina, Alberto Burgos-Edwards, Cristina Theoduloz, Satyajit Tripathy, Motlalepula Gilbert Matsabisa and Guillermo Schmeda-Hirschmann
Antioxidants 2024, 13(10), 1219; https://doi.org/10.3390/antiox13101219 - 10 Oct 2024
Viewed by 1297
Abstract
Herbal teas are used in South Africa as digestives to lower glycaemia and for other indications. However, the chemical composition of the infusions and their effect on enzymes related to metabolic syndrome is poorly known. The composition of infusions and methanol extracts of [...] Read more.
Herbal teas are used in South Africa as digestives to lower glycaemia and for other indications. However, the chemical composition of the infusions and their effect on enzymes related to metabolic syndrome is poorly known. The composition of infusions and methanol extracts of B. saligna (Scrophulariaceae), Lippia javanica, L. scaberrima, and Phyla dulcis (Verbenaceae) was assessed and the effect of the infusions and extract was determined towards α-glucosidase, α-amylase, and pancreatic lipase. The commercial herbal products were extracted separately with MeOH or hot water to obtain the extract/infusion for comparative studies. Total phenolic, total flavonoid and antioxidant capacity were assessed. The fingerprints of the MeOH extracts and infusions were compared by HPLD-DAD. The extract constituents were tentatively identified by HPLC-MS/MS and NMR analyses. From the extracts/infusions, 57 compounds were identified, including iridoids, phenylpropanoid glycosides, flavonoids, and caffeic acid derivatives, among others. The MeOH extracts and infusions showed strong inhibition towards α-glucosidase with IC50 in the range of 0.13–0.84 µg/mL for the phenolic-enriched infusion extract (PEI) and 0.47–0.50 µg/mL for the MeOH extracts, respectively. The P. dulcis PEI showed higher inhibition towards α-glucosidase, and the MeOH extract of L. scaberrima was better than the PEI. At 100 µg/mL, the PEI from the four herbal teas reduces the activity of α-amylase by 23.03–28.61%, with L. javanica as the most active tea. Three of the species are high in phenylpropanoid glycosides, while P. dulcis contains rosmarinic acid. Some 26 compounds were identified in the infusion from B. saligna, 28 from L. scaberrima, and 21 from P. dulcis. Four of them are common in all the teas, namely decaffeoylverbascoside, verbascoside, isoverbascoside, and tuberonic acid hexoside. Ten compounds occur in two of the teas and seventeen, fifteen, and eleven compounds were detected only in B. saligna, L. scaberrima, and P. dulcis, respectively. Most of the compounds are reported for the first time from the crude drug infusions. The results give some support for the traditional use of herbal teas as digestives and/or indications for diabetes. The chemical fingerprints set the basis for quality control of the crude drugs, based on the main constituents and differential compounds occurring in the samples. Full article
(This article belongs to the Special Issue Potential Health Benefits of Dietary Antioxidants)
Show Figures

Figure 1

Figure 1
<p><sup>1</sup>H NMR spectra of the infusions from <span class="html-italic">Buddleja saligna</span>, <span class="html-italic">Lippia javanica</span>, <span class="html-italic">L. scaberrima</span>, and <span class="html-italic">Phyla dulcis</span> (400 MHz, DMSO-d6).</p>
Full article ">Figure 1 Cont.
<p><sup>1</sup>H NMR spectra of the infusions from <span class="html-italic">Buddleja saligna</span>, <span class="html-italic">Lippia javanica</span>, <span class="html-italic">L. scaberrima</span>, and <span class="html-italic">Phyla dulcis</span> (400 MHz, DMSO-d6).</p>
Full article ">Figure 1 Cont.
<p><sup>1</sup>H NMR spectra of the infusions from <span class="html-italic">Buddleja saligna</span>, <span class="html-italic">Lippia javanica</span>, <span class="html-italic">L. scaberrima</span>, and <span class="html-italic">Phyla dulcis</span> (400 MHz, DMSO-d6).</p>
Full article ">Figure 1 Cont.
<p><sup>1</sup>H NMR spectra of the infusions from <span class="html-italic">Buddleja saligna</span>, <span class="html-italic">Lippia javanica</span>, <span class="html-italic">L. scaberrima</span>, and <span class="html-italic">Phyla dulcis</span> (400 MHz, DMSO-d6).</p>
Full article ">Figure 2
<p>HPLC-DAD profiles of <span class="html-italic">Buddleja saligna</span>, <span class="html-italic">Lippia javanica</span>, <span class="html-italic">L. scaberrima</span>, and <span class="html-italic">Phyla dulcis</span> infusions at 330 and 360 nm. Compounds: A: verbascoside; B: Quercetin 3-<span class="html-italic">O</span>-glucoside; C: isoverbascoside; D: flavonoid; E: Quercetin derivative; F: Rosmarinic acid.</p>
Full article ">Figure 3
<p>HPLC-ESI-MS/MS chromatograms of <span class="html-italic">Buddleja saligna</span> (<b>A</b>), <span class="html-italic">Lippia scaberrima</span> (<b>B</b>), and <span class="html-italic">Phyla dulcis</span> (<b>C</b>). For the identity of the compounds please see <a href="#antioxidants-13-01219-t005" class="html-table">Table 5</a>.</p>
Full article ">Figure 4
<p>Structure of some compounds identified/tentatively identified from the selected South African teas.</p>
Full article ">Figure 4 Cont.
<p>Structure of some compounds identified/tentatively identified from the selected South African teas.</p>
Full article ">
29 pages, 1043 KiB  
Review
Inquiry of the Metabolic Traits in Relationship with Daily Magnesium Intake: Focus on Type 2 Diabetic Population
by Ana-Maria Gheorghe, Mihai-Lucian Ciobica, Claudiu Nistor, Maria-Magdalena Gurzun, Bianca-Andreea Sandulescu, Mihaela Stanciu, Florina Ligia Popa and Mara Carsote
Clin. Pract. 2024, 14(4), 1319-1347; https://doi.org/10.3390/clinpract14040107 - 8 Jul 2024
Viewed by 1671
Abstract
Magnesium (Mg), an essential nutrient with a wide area of physiological roles, stands as a cofactor in over 600 enzymatic reactions involved in the synthesis of proteins and nucleic acids, DNA repair, neuromuscular functions, neuronal transmission, cardiac rhythm regulation, and the modulation of [...] Read more.
Magnesium (Mg), an essential nutrient with a wide area of physiological roles, stands as a cofactor in over 600 enzymatic reactions involved in the synthesis of proteins and nucleic acids, DNA repair, neuromuscular functions, neuronal transmission, cardiac rhythm regulation, and the modulation of metabolic pathways, as well as acting as a natural blocker for the calcium channels. Our objective was to highlight the most recent clinical data with respect to daily Mg intake (DMI) and metabolic traits, particularly type 2 diabetes mellitus (DM). This was a PubMed-based review of the English-language medical papers across different key terms of search; the time frame was from January 2019 until April 2024. We included (clinically relevant) original studies and excluded cases reports, series, reviews, editorials, opinion, experimental studies, and non-human data as well as studies that did not specifically assessed DMI and only provided assays of serum Mg, studies on patients diagnosed with type 1 or secondary DM. A total of 30 studies were included and we organized the key findings into several sections as follows. Studies investigating DMI in relationship with the adherence to local recommendations in diabetic subjects (n = 2, one transversal and another retrospective cohort; N = 2823) found that most of them had lower DMI. Deficient DMI was correlated with the risk of developing/having DM across five studies (n = 5, one prospective and four of cross-sectional design; N = 47,166). An inverse correlation between DMI and DM prevalence was identified, but these data are presented amid a rather heterogeneous spectrum. Four novel studies (N = 7279) analysed the relationship between DMI and DM control according to various methods (HbA1c, fasting and postprandial glycaemia, and insulin); the association may be linear in diabetic subjects only at certain levels of DMI; additionally, the multifactorial influence on HBA1c should take into consideration this dietary determinant, as well, but there are no homogenous results. Three studies concerning DMI and diabetic complications (one cross-sectional, one prospective, and another case–control study) in terms of retinopathy (n = 1, N = 3794) and nephropathy (n = 2, N = 4805) suggested a lower DMI was associated with a higher risk of such complications. Additionally, two other studies (one prospective and one retrospective cohort) focused on mortality (N = 6744), which, taking only certain mortality indicators into consideration, might be decreased in the subgroups with a higher DMI. Seven studies (N = 30,610) analysed the perspective of DMI in the general population with the endpoint of different features amid glucose profile, particularly, insulin resistance. Concerning HOMA-IR, there were three confirmatory studies and one non-confirmatory, while fasting plasma glucose was highlighted as inversely correlated with a DMI (n = 1). The highest level of evidence regarding Mg supplementation effects on glucose metabolism stands on seven randomised controlled trials (N = 350). However, the sample size was reduced (from 14 to 86 individuals per study, either diabetic or pre-diabetic) and outcomes were rather discordant. These clinical aspects are essential from a multidisciplinary perspective and further trials are mandatory to address the current areas of discordant results. Full article
(This article belongs to the Special Issue Clinical Nutrition in Metabolic Disorders)
Show Figures

Figure 1

Figure 1
<p>Magnesium regulates by being an enzyme co-factor insulin secretion and receptor effects as well as oxidative stress and inflammatory profile, all of which might be impaired amid the detection of type 2 diabetes [<a href="#B22-clinpract-14-00107" class="html-bibr">22</a>,<a href="#B23-clinpract-14-00107" class="html-bibr">23</a>,<a href="#B24-clinpract-14-00107" class="html-bibr">24</a>,<a href="#B25-clinpract-14-00107" class="html-bibr">25</a>].</p>
Full article ">Figure 2
<p>The key findings across selected studies according to the mentioned methods.</p>
Full article ">Figure 3
<p>Sneak peak of magnesium interplay and type 2 diabetes mellitus amid the co-presence of metabolic syndrome and associated high cardiovascular risk.</p>
Full article ">
10 pages, 624 KiB  
Article
Supplementation with Highly Standardized Cranberry Extract Phytosome Achieved the Modulation of Urinary Tract Infection Episodes in Diabetic Postmenopausal Women Taking SGLT-2 Inhibitors: A RCT Study
by Mariangela Rondanelli, Francesca Mansueto, Clara Gasparri, Sebastiano Bruno Solerte, Paola Misiano and Simone Perna
Nutrients 2024, 16(13), 2113; https://doi.org/10.3390/nu16132113 - 2 Jul 2024
Cited by 1 | Viewed by 2816
Abstract
Urinary tract infections (UTIs) are the most common bacterial infections in postmenopausal women, and women with diabetes are possibly at a higher risk. The aim of this study is to evaluate the potential benefit on the prevention of UTI episodes, assessed by urinalysis [...] Read more.
Urinary tract infections (UTIs) are the most common bacterial infections in postmenopausal women, and women with diabetes are possibly at a higher risk. The aim of this study is to evaluate the potential benefit on the prevention of UTI episodes, assessed by urinalysis and urine culture (primary outcome) after two, four and six months, of daily oral dietary supplement (120 mg highly standardized cranberry extract phytosome), compared to placebo, in diabetic postmenopausal women taking SGLT-2 inhibitors. Forty-six subjects (mean age 72.45 ± 1.76) completed the study (23 placebo/23 supplement). Considering UTI episodes, during the six-month supplementation period, an increase of 1.321 (95% CI: −0.322; 2.9650) was observed in the placebo group, while it remained at a steady value of 0.393 (95% CI: −4.230; 5.016) in the supplemented group. Regarding UTI episodes, in both groups, interaction between times for supplementation was statistically significant (p = 0.001). In particular, at follow-up 4, 9% of the placebo group showed infection versus only 3% with cranberry supplementation. Glycaemia and glycated hemoglobin values (secondary outcomes) were not modified at the end of six months with respect to the basal values in both groups, as expected. While in terms of quality of life per the SF-12 health questionnaire, there were no differences between the two groups, an improvement in SF-12 quality of life was observed in both groups (six months vs. basal). In conclusion, highly standardized cranberry extract phytosome supplementation reduced UTI recurrence. Full article
(This article belongs to the Section Phytochemicals and Human Health)
Show Figures

Figure 1

Figure 1
<p>Flow diagram of the study.</p>
Full article ">Figure 2
<p>UTI episodes during the six-month supplementation.</p>
Full article ">
17 pages, 684 KiB  
Article
Glycaemic Response to a Nut-Enriched Diet in Asian Chinese Adults with Normal or High Glycaemia: The Tū Ora RCT
by Ivana R. Sequeira-Bisson, Louise W. Lu, Marta P. Silvestre, Lindsay D. Plank, Nikki Middleditch, Alejandra Acevedo-Fani, Amber Parry-Strong, Kieren G. Hollingsworth, Alexander Tups, Jennifer L. Miles-Chan, Jeremy D. Krebs, Meika Foster and Sally D. Poppitt
Nutrients 2024, 16(13), 2103; https://doi.org/10.3390/nu16132103 - 1 Jul 2024
Cited by 1 | Viewed by 2218
Abstract
Nut-based products are a good source of high-quality plant protein in addition to mono- and polyunsaturated fatty acids, and may aid low-glycaemic dietary strategies important for the prevention of type 2 diabetes (T2D). In particular, they may be advantageous in populations susceptible to [...] Read more.
Nut-based products are a good source of high-quality plant protein in addition to mono- and polyunsaturated fatty acids, and may aid low-glycaemic dietary strategies important for the prevention of type 2 diabetes (T2D). In particular, they may be advantageous in populations susceptible to dysglycaemia, such as Asian Chinese. The present study aimed to compare effects of a higher-protein nut bar (HP-NB, also higher in total fibre and unsaturated fats, comprising mixed almonds and peanuts) vs. an isoenergetic higher-carbohydrate cereal bar (HC-CB) within the diet of 101 Chinese adults with overweight and normo- or hyperglycaemia. Ectopic pancreas and liver fat were characterised using magnetic resonance imaging and spectroscopy (MRI/S) as a secondary outcome. Participants were randomized to receive HP-NB or HC-CB daily as a 1 MJ light meal or snack replacement, in addition to healthy eating advice. Anthropometry and clinical indicators of T2D risk were assessed fasted and during an oral glucose tolerance test (OGTT), pre- and post-intervention. No significant difference was observed between diet groups for body weight, body mass index, waist or hip circumference, blood pressure, glucoregulatory markers, lipid profile or inflammatory markers over 12 weeks (all, p > 0.05). No difference was observed between glycaemic subgroups or those with normal versus high ectopic organ fat. Although HP-NB can attenuate postprandial glycaemia following a meal, no effects were observed for either fasting or glucose-mediated outcomes following longer-term inclusion in the habitual diet of Chinese adults with overweight, including at-risk subgroups. Full article
(This article belongs to the Section Nutrition and Diabetes)
Show Figures

Figure 1

Figure 1
<p>Study design. CHO, carbohydrate; CID, clinical investigation day; Wk, week; OGTT, oral glucose tolerance test; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; and DXA, dual-energy X-ray absorptiometry.</p>
Full article ">Figure 2
<p>CONSORT flowchart of participants. AKL: Auckland site; CID1: clinical investigation day 1/baseline; HC-CB: higher-CHO cereal bar; HP-NB: higher-protein nut bar; and WLG: Wellington site.</p>
Full article ">
9 pages, 1260 KiB  
Article
Potential Celiac Disease in Children: Health Status on A Long-Term Gluten-Containing Diet
by Roberta Mandile, Federica Lerro, Martina Carpinelli, Lorenzo D’Antonio, Luigi Greco, Riccardo Troncone and Renata Auricchio
Nutrients 2024, 16(11), 1708; https://doi.org/10.3390/nu16111708 - 30 May 2024
Viewed by 1298
Abstract
Potential celiac disease (PCD) is a clinical condition characterised by the presence of a positive CD-specific serology and a normal intestinal architecture. Asymptomatic PCD patients are generally advised to continue on a gluten-containing diet (GCD), but long-term risks of this approach have never [...] Read more.
Potential celiac disease (PCD) is a clinical condition characterised by the presence of a positive CD-specific serology and a normal intestinal architecture. Asymptomatic PCD patients are generally advised to continue on a gluten-containing diet (GCD), but long-term risks of this approach have never been explored. In the present study, we aimed to investigate nutritional and autoimmune complications possibly developing overtime in a cohort of asymptomatic PCD children on a GCD. We compared children’s parameters of growth, nutritional status, and autoimmunity between the time of diagnosis and on the occasion of their last medical check, after a long-term gluten-containing diet. Altogether, we collected data from 171 PCD children with a mean follow-up time of 3 years (range 0.35–15.3 years). During follow-up, although patients did not reduce their amount of daily gluten intake, their anti-tissue transglutaminase (anti-TG2) antibodies spontaneously and significantly decreased. Most parameters analysed had not changed during follow-up (height centile, ferritin, albumin, cholesterol, calcium, alkaline phosphatase, parathormone, and vitamin D) or even improved significantly (weight and BMI centile, haemoglobin, blood iron, HDL, glycaemia, and HbA1C, p < 0.05), always remaining within the limit of normality. Equally, autoantibodies for other concomitant autoimmune disorders did not increase overtime. Similar results were obtained excluding from analysis patients who had stopped producing anti-TG2 and those with a follow-up time < 3 years. Our pilot study has provided reassuring results regarding the maintenance of a gluten-containing diet in asymptomatic PCD children, even when long-term follow-up was considered. Full article
(This article belongs to the Section Pediatric Nutrition)
Show Figures

Figure 1

Figure 1
<p>Flow chart of study cohort. GFD: gluten-free diet. VA: villous atrophy.</p>
Full article ">Figure 2
<p>Parameters between time of diagnosis (T0) and on occasion of last follow-up (Tx). * significance <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.005, *** <span class="html-italic">p</span> &lt; 0.0005, **** <span class="html-italic">p</span> &lt; 0.00005. Ct: centile, Hb: haemoglobin, HbA1C%: glycated haemoglobin, ALP: alkaline phosphatase, PTH: parathormone, HDL: high density lipoprotein.</p>
Full article ">
11 pages, 397 KiB  
Article
De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test
by Barbora Pavlikova, Martina Breburdova, Michal Krcma, Miroslav Kriz, Jan Kasparek and Zdenek Rusavy
Life 2024, 14(5), 568; https://doi.org/10.3390/life14050568 - 28 Apr 2024
Viewed by 1128
Abstract
Background: Successful conversion from insulin therapy to glucagon-like peptide 1 receptor agonist (GLP-1RA) with basal insulin in well-controlled patients has already been demonstrated. However, the data concerning individuals with poor glycaemic control are scarce. The aim of this work was to assess the [...] Read more.
Background: Successful conversion from insulin therapy to glucagon-like peptide 1 receptor agonist (GLP-1RA) with basal insulin in well-controlled patients has already been demonstrated. However, the data concerning individuals with poor glycaemic control are scarce. The aim of this work was to assess the success rate of insulin therapy to liraglutide transition in poorly controlled diabetes in a real-world clinical setting and to define predictors of success. We are the first to present the method of a fasting test as a way to identify the patients at higher risk of failure after treatment de-intensification. Methods: The retrospective observational study analyzed data of 62 poorly controlled obese diabetic patients on high-dose insulin therapy, who were subjected to a 72 h fasting test during hospitalization and subsequently switched to liraglutide ± basal insulin therapy. During the fasting, all antidiabetic treatment was discontinued. Patients were classified as responders if they remained on GLP-1RA treatment after 12 months. Non-responders restarted the basal-bolus insulin (BBI) regimen. Development of glycated hemoglobin (HbA1c) and body weight in both groups, alongside with parameters associated with the higher risk of return to the BBI regimen, were analyzed. Results: A total of 71% of patients were switched successfully (=responders). Responders had more significant improvement in HbA1c (−6.4 ± 19.7 vs. −3.4 ± 22.9 mmol/mol) and weight loss (−4.6 ± 7.1 vs. −2.5 ± 4.0). Statistically significant difference between groups was found in initial HbA1c (75.6 ± 17.9 vs. 90.5 ± 23.6; p = 0.04), total daily dose of insulin (67.6 ± 36.4 vs. 90.8 ± 32.4; p = 0.02), and mean glycaemia during the fasting test (6.9 ± 1.7 vs. 8.6 ± 2.2 mmol/L; p < 0.01). Conclusions: This study confirms that therapy de-intensification in poorly controlled patients with a BBI regimen is possible. Higher baseline HbA1c, total daily insulin dose, and mean glucose during fasting test are negative predictive factors of successful therapy de-escalation. Full article
Show Figures

Figure 1

Figure 1
<p>Study flow chart. GLP-1RA, glucagon-like peptide 1 agonists. BBI, basal bolus insulin regimen.</p>
Full article ">
80 pages, 2344 KiB  
Review
Overview of Ethnobotanical–Pharmacological Studies Carried Out on Medicinal Plants from the Serra da Estrela Natural Park: Focus on Their Antidiabetic Potential
by Radhia Aitfella Lahlou, Filomena Carvalho, Maria João Pereira, João Lopes and Luís R. Silva
Pharmaceutics 2024, 16(4), 454; https://doi.org/10.3390/pharmaceutics16040454 - 25 Mar 2024
Cited by 2 | Viewed by 3240
Abstract
The Serra da Estrela Natural Park (NPSE) in Portugal stands out as a well-preserved region abundant in medicinal plants, particularly known for their pharmaceutical applications in diabetes prevention and treatment. This comprehensive review explores these plants’ botanical diversity, traditional uses, pharmacological applications, and [...] Read more.
The Serra da Estrela Natural Park (NPSE) in Portugal stands out as a well-preserved region abundant in medicinal plants, particularly known for their pharmaceutical applications in diabetes prevention and treatment. This comprehensive review explores these plants’ botanical diversity, traditional uses, pharmacological applications, and chemical composition. The NPSE boast a rich diversity with 138 medicinal plants across 55 families identified as traditionally and pharmacologically used against diabetes globally. Notably, the Asteraceae and Lamiaceae families are prevalent in antidiabetic applications. In vitro studies have revealed their significant inhibition of carbohydrate-metabolizing enzymes, and certain plant co-products regulate genes involved in carbohydrate metabolism and insulin secretion. In vivo trials have demonstrated antidiabetic effects, including glycaemia regulation, insulin secretion, antioxidant activity, and lipid profile modulation. Medicinal plants in NPSE exhibit various activities beyond antidiabetic, such as antioxidant, anti-inflammatory, antibacterial, anti-cancer, and more. Chemical analyses have identified over fifty compounds like phenolic acids, flavonoids, terpenoids, and polysaccharides responsible for their efficacy against diabetes. These findings underscore the potential of NPSE medicinal plants as antidiabetic candidates, urging further research to develop effective plant-based antidiabetic drugs, beverages, and supplements. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Geolocalization of Serra da Estrela Natural Park [<a href="#B106-pharmaceutics-16-00454" class="html-bibr">106</a>].</p>
Full article ">Figure 2
<p>Diagram of the systematic literature review.</p>
Full article ">Figure 3
<p>Families containing the highest number of species with antidiabetic potential (out of 888) in NPSE.</p>
Full article ">
8 pages, 424 KiB  
Brief Report
Impact of Intensive Lifestyle Intervention on Remission of Metabolic Syndrome, Prediabetes, Diabetes, and Hypertension in Adults Living with Obesity
by Pierre-Olivier Magnan, Josep Iglesies-Grau, Élise Latour, Valérie Guilbeault, Anil Nigam, Martin Juneau, Louis Bherer and Mathieu Gayda
Obesities 2024, 4(1), 1-8; https://doi.org/10.3390/obesities4010001 - 26 Feb 2024
Viewed by 2004
Abstract
Background: Lifestyle intervention programs have long been shown to be effective in preventing cardiometabolic risk factors (CMRFs) such as metabolic syndrome (MS), impaired fasting glycaemia (IFG), type II diabetes (T2DM), and hypertension (HTA). However, their potential for remission of these CMRFs in overweight/obese [...] Read more.
Background: Lifestyle intervention programs have long been shown to be effective in preventing cardiometabolic risk factors (CMRFs) such as metabolic syndrome (MS), impaired fasting glycaemia (IFG), type II diabetes (T2DM), and hypertension (HTA). However, their potential for remission of these CMRFs in overweight/obese adults is less clear. The importance of attaining remission has significantly increased as these CMRFs are more and more prevalent. Objectives: The aim of this study is to determine the impact of an intensive lifestyle intervention program on the remission of MS, IFG, T2DM, and HTA in overweight/obese adults. Methods: Forty participants living with overweight/obesity were enrolled in an 18-month multidisciplinary primary prevention body mass loss intervention program. MS, IFG, T2DM, and HTA statuses were assessed at baseline, 9 months, and the end of the program. Results: At baseline, 25 participants (64.1%) had MS, 7 (17.9%) had IFG, 4 (10.2%) were living with diabetes, and 28 (70.0%) had HTA. At 18 months, six (24%) of the participants living with MS, two (28.6%) of the participants with IFG, two (50%) of the participants with diabetes, and two (7.1%) of the participants with HTA met all criteria for remission. Conclusion: An intensive lifestyle intervention program consisting of monitored exercise training and lifestyle modification counselling has great potential for achieving remission of CMRFs in adults living with overweight/obesity. Full article
Show Figures

Figure 1

Figure 1
<p>Number of participants in remission of (<b>A</b>) MS, (<b>B</b>) IFG and T2DM, and (<b>C</b>) HTA at baseline, 9 months, and 18 months. Black lines represent participants without CMRFs; dark grey lines represent participants with either MS, T2DM, or HTA; grey lines represent participants with prediabetes and pale grey lines represent participants in remission. MS: metabolic syndrome, IFG: impaired fasting glycaemia, T2DM: type II diabetes, HTA: hypertension.</p>
Full article ">
Back to TopTop